Merck to acquire US biopharma CDMO Exelead for $780m
Pharma giant Merck has signed an all-cash deal worth around $780 million to acquire Exelead, an Indiana-based biopharmaceutical contract development and manufacturing organization (biopharma CDMO). Exelead is said to have specialization in complex injectable formulations, which include Lipid Nanoparticle (LNP) based drug delivery technology. According to Merck, LNP-based technology is important in mRNA therapeutics for […]